Study Group: Hepatologists (US)(?)
Council Members in this Study Group: 84
Request a survey with this Study Group
Leading Experts in this Study Group
Hepatologist and Gastroenterologist
Miami Gastroenterology Consultants PA
Miguel Rodriguez, MD, is a Hepatologist & Gastroenterologist, Managing Partner of Miami Gastroenterology Consultants, PA., a single specialty group in Miami, Florida. He is former Assistant Professor of Medicine of the University of Miami School of Medicine and Center for Liver Diseases and Division...
Associate Professor of Clinical Medicine
Georgetown University - CC
Averell Sherker, MD, FRCP, is Director of the Center for Liver Diseases at Washington Hospital Center in Washington, DC. He is also Associate Professor of Clinical Medicine at Georgetown University. Previously, Dr. Sherker was Director of Hepatology Research at the McGill University in Canada, where...
Eugene Schiff, MD, MACP, FRCP, MACGDirector of Center for Liver Diseases
University of Miami School of Medicine
Eugene Schiff, MD, MACP, FRCP, FAGA, MACG, AGAF, is a Leonard Miller Professor of Medicine and Director of the Center for Liver Diseases at the University of Miami School of Medicine. Dr. Schiff is fellowship trained in gastroenterology. He is the co-editor of the tenth edition of Schiff’s Diseases...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Gastroenterologists (US) | 820 |
| Physicians who Treat GERD (US) | 359 |
| Gastroenterologists who Treat GERD | 367 |
| Physicians who Treat HCV (US) | 90 |
| Prescribers of Pegasys | 31 |
| IBD Gastroenterologists (US) | 167 |
| IBD Gastroenterologists | 303 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
New Drug Discovery Pact with GVK BIO allows Wyeth to increase its Biotechnical Capacity.
Biotechnological Products have been emerging rapidly in the US/global drug market ever since the emergence of Genetech (ticker:DNA) and its break out drugs Rituxan (rituximab) and TNKase (tenecteplase). Since then, both brandname (ie Pfizer and Merck) as well as...
In the two large phase 3 registration trials of albinterferon alfa-2b (Albuferon, Human Genome Sciences), called ACHIEVE-1 and ACHIEVE-2/3, several patients in the arm using Albuferon 1200 mcg per 2 weeks + RBV were found to have serious pulmonry adverse events. Such serious events were not...
IDEAL study shows equivalent efficacy of Ribavirin + PEG-Intron 1.5 vs. 1.0 mcg/kg vs. Pegasys for HCV genotype 1
The IDEAL study compared combination therapy of ribavirin (RBV) plus PEG-Intron (Schering) at 1.5 mcg/kg weekly vs. 1.0 mcg/kg vs. Pegasys (Roche) 180 mcg weekly in treatment-naive HCV genotype 1 patients. The primary outcome of SVR rate was similar: 40% vs. 38% vs. 41%. ...
Hepatitis C: little-recognized nitazoxanide (Alinia, Romark) shows remarkable activity in combination therapy for HCV genotype 4
A phase 2 study in Egypt of hepatitis C genotype 4 showed that the viral cure or SVR rate (here actually SVR12 = %HCV RNA negative at post-Rx week 12, real SVR is at week 24) is much improved when nitazoxanide is added to standard therapy. SVR12 was 79% in nitazoxanide + Pegasys + ribavirin...
First announcement of data (very limited) from InterMune's HCV protease inhibitor ITMN-191
In the phase 1a (single ascending dose, SAD) trial, ITMN-191 was found to be safe in the first doses tested, and more cohorts will be tested with higher doses. Details of the study will be presented later in quarter 1 of 2008. Multiple ascending doses (MAD) in a 2-week monotherapy phase...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Government/Military Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Professor
- Partner
- Chief Executive Officer